Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Systemic Sclerosis Associated Polyarthritis
NCT01748084Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2013
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Rituximab with Placebo (2 arms). Primary endpoint: Number of tender and swollen joints at 6 months. Started Apr 2013; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01748084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748084.